A clinicopathologic study of @entity1 with hemorrhagic XXXX treated with selective coronary thrombolysis with urokinase.

@entity1 @entity548 @entity1188 @entity583 @entity850 @entity204 @entity385 @entity2798
Hemorrhagic @entity583 ( @entity583 ) was studied after @entity2798 ( @entity2798 ) in 30 @entity1 undergoing autopsy. Urokinase, 240,000 to 1,200,000 U, was selectively injected into the @entity1188 -related coronary artery at 2 to 9 hr (4 +/- 2 hr) after the onset of @entity583 . The @entity1188 -related coronary artery showed complete occlusion in 21, 99% @entity850 in eight, and 90% @entity850 in one @entity1 before @entity2798 . After @entity2798 , complete occlusion was seen in only five, 99% @entity850 in 22, and 90% @entity850 in three @entity1 . Twenty-eight @entity1 had transmural @entity1188 and the other two had @entity1188 . Macroscopically and microscopically, the degree of @entity548 was classified as no, slight, moderate, or marked bleeding and the @entity385 was defined as moderate or marked @entity548 in the @entity1188 area. According to the interval from @entity2798 to @entity204 , @entity1 were also classified into stage I (early acute stage, 1 to 4 hr after @entity2798 and 4 to 13 hr after the onset of @entity583 ; n = 7), stage II (late acute stage, 9 hr to 11 days after @entity2798 and 15 hr to 11 days after the onset of @entity583 ; n = 18), or stage III (old @entity1188 stage, over 17 days after @entity583 and @entity2798 ; n = 5). There were no significant differences with respect to the frequency of recanalization, the time from the onset of @entity583 to @entity2798 , the dose of urokinase, or other clinical parameters among @entity1 at the three stages. Only the hearts of @entity1 in stage II showed @entity385 , and it was found in 15 of 18 of these hearts.(ABSTRACT TRUNCATED AT 250 WORDS)
